超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

日本參天制藥Santen Pharmaceutical 
參天制藥從1890年創(chuàng)業(yè)開始，作為一個從事處方藥品以及非處方藥品的研究、開發(fā)、生產(chǎn)、銷售的企業(yè)，一直為人們的眼睛和身體的健康保持和提高作出著不斷的貢獻(xiàn)。
現(xiàn)在，作為一個集中致力于眼科和風(fēng)濕病的專業(yè)性企業(yè)，在占本公司銷售額80%的眼科處方藥領(lǐng)域，我們針對所有的眼科疾病開發(fā)生產(chǎn)優(yōu)質(zhì)的醫(yī)藥品，并根據(jù)醫(yī)療現(xiàn)場的需求積極提供信息，在日本國內(nèi)取得了No.1的地位。
此外，以眼科處方藥事業(yè)為中心，已在日本美國歐洲三方面構(gòu)筑了臨床開發(fā)·銷售體制，提供給世界以卓越的研究開發(fā)能力為根本的有獨特性的產(chǎn)品，成為在世界上有存在意義的企業(yè)是我們的目標(biāo)。

■處方藥
[眼科處方藥]
在日本國內(nèi)的市場占有率約為4成，是眼科處方藥市場的領(lǐng)導(dǎo)者。我們具備符合醫(yī)療現(xiàn)場需求的多種疾病領(lǐng)域的治療藥，擁有國內(nèi)最多的MR(醫(yī)藥信息擔(dān)當(dāng)者)和有絕對優(yōu)勢的信息提供和收集能力，為日本全國的眼科醫(yī)生提供細(xì)致的服務(wù)。在海外，美國、歐洲、亞洲等各國都擁有基地，進(jìn)行眼科藥的開發(fā)、生產(chǎn)和銷售．

[抗風(fēng)濕藥]
參天制藥的另一個支柱是抗風(fēng)濕藥品領(lǐng)域。在關(guān)節(jié)風(fēng)濕治療領(lǐng)域里我們向醫(yī)療現(xiàn)場提供被稱為DMARDs（Disease Modifying Anti-rheumatic Drugs：疾病修飾性抗風(fēng)濕藥）的3個品種的處方藥。同時在加強(qiáng)研究開發(fā)繼這3個品種之后的新抗風(fēng)濕藥品。

■非處方藥
1897年「大學(xué)眼藥」開始銷售以來，參天制藥100多年來著眼于簡易治療和眼病預(yù)防進(jìn)行了非處方滴眼劑的開發(fā)、生產(chǎn)、銷售。并從提高便利性的角度出發(fā)，將很多具有獨創(chuàng)性的構(gòu)思應(yīng)用到了產(chǎn)品當(dāng)中，1962年在日本率先采用塑料材質(zhì)的滴眼劑容器是一個具有代表性的例子。主要的產(chǎn)品有「SenteFXneo」、「Santedo」系列、「Sante40」系列等．

■醫(yī)療器械
作為眼科領(lǐng)域的專家，對醫(yī)療機(jī)構(gòu)提供醫(yī)藥品以外的產(chǎn)品、服務(wù)，這一醫(yī)療器械事業(yè)也是參天制藥的一個強(qiáng)項。主要銷售白內(nèi)障手術(shù)所使用的超音波白內(nèi)障手術(shù)裝置，眼內(nèi)鏡片，手術(shù)用的一些物品等。2001年11月，收購了以眼內(nèi)鏡片的研究、開發(fā)、生產(chǎn)、銷售為主的美國的Advanced?Vision?Science?Inc．，進(jìn)一步加強(qiáng)了眼內(nèi)鏡片的產(chǎn)品開發(fā)力量．

[Prescription Ophthalmics]
Santen leads the Japanese market for prescription ophthalmics with a share of nearly 40 percent. We offer treatments for a wide range of ophthalmic disorders and covers ophthalmologists nationwide with the largest number of medical representatives in Japan. We also have overseas bases in the United States, Europe and Asian countries for the development, production and sale of ophthalmic pharmaceuticals.

[Anti-rheumatic Pharmaceuticals]
Santen's second largest business area is anti-rheumatic pharmaceuticals, and we provide three disease modifying anti-rheumatic drugs (DMARDs) to healthcare institutions throughout Japan for the treatment of rheumatoid arthritis. Furthermore, we are strengthening our research and development efforts to develop new anti-rheumatic drugs to succeed these two products.

Over-the-Counter (OTC) Pharmaceuticals

Since the launch of Daigaku Eye Drops in 1899, Santen has been committed to the development, production and marketing of superior OTC ophthalmic products, with a focus on basic treatment and eye disease prevention. A consistent emphasis on creativity and innovation, such as introducing Japan's first plastic eye drop container in 1962, highlights Santen's determination to put numerous innovative ideas into practice. Major OTC products include Sante FX Neo , the Sante de u series and the Sante 40 series, which have been well-recognized among Japanese consumers for many years.

Medical Devices

Santen participates in the ophthalmic devices market as an expert in the field of ophthalmology, and the ability to provide products and services to medical institutions in addition to pharmaceuticals illustrates our strength. Our main products include phacoemulsification machines for cataract surgery, intraocular lenses and surgical instruments. In November 2001, Santen strengthened its ability to develop intraocular lenses by acquiring the U.S. company Advanced Vision Science, Inc., which is involved in the research, development, production and marketing of intraocular lenses.